Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | RARA | P10276 | 3/20 | 0.38 |
| ▸ | RARB | P10826 | 3/20 | 0.38 |
| ▸ | RARG | P13631 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14822713 | 0.91 | RARA (0.36) | PPARGRARARARBRARGPPARA | |
| SCHEMBL14666658 | 0.84 | MAOB (0.37) | PPARGRARARARBRARGPPARA | |
| SCHEMBL3030838 | 0.77 | KDM4E (0.41) | PPARGRARARARBRARGPPARA | |
| SCHEMBL3023787 | 0.77 | PTGS2 (0.39) | RARARARBRARGHIF1AEPAS1 | |
| SCHEMBL12082011 | 0.76 | RARA (0.46) | PPARGRARARARBRARGMAOB | |
| SCHEMBL3027979 | 0.75 | NR3C2 (0.49) | RARARARBRARGCYP2D6PTGS2 | |
| SCHEMBL3027541 | 0.75 | PTGS2 (0.43) | RARARARBRARGCNR2PTGS2 | |
| SCHEMBL3023515 | 0.75 | RARA (0.38) | PPARGRARARARBRARGPPARA | |
| SCHEMBL3027431 | 0.75 | NPC1 (0.40) | PPARGRARARARBRARGHIF1A | |
| SCHEMBL14666717 | 0.74 | RARA (0.38) | PPARGRARARARBRARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | PPARG 390/4885RARA 640/4885RARB 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.